---
title: "Kisqali (ribociclib), all indications: Pharmacology questions"
description: "Pharmacology questions on Kisqali (ribociclib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Kisqali work (mechanism of action)? How is Kisqali metabolized? What is the half-life of Kisqali? How is Kisqali eliminated from the body? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/kisqali/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Kisqali (ribociclib), all indications: Pharmacology questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)  
Indication pages: [HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)

## Mechanism

<a id="kisqali-mechanism"></a>

### How does Kisqali work (mechanism of action)?

> “Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins 
> and are downstream of signaling pathways which lead to cell cycle progression and cellular proliferation. The cyclin D-
> CDK4/6 complex regulates cell cycle progression through phosphorylation of the retinoblastoma protein (pRb).  
> In vitro, ribociclib decreased pRb phosphorylation, resulting in arrest in the G1 phase of the cell cycle and reduced 
> proliferation in breast cancer-derived models.”

Source: [KISQALI: Prescribing information, page 19, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=19)

> “In studies 
> using patient-derived estrogen receptor positive breast cancer xenograft models, combination of ribociclib and antiestrogen 
> (e.g., letrozole) therapies resulted in increased tumor growth inhibition compared to each drug alone. Additionally, the 
> combination of ribociclib and fulvestrant resulted in tumor growth inhibition in an estrogen receptor positive breast cancer 
> xenograft model.”

Source: [KISQALI: Prescribing information, page 20, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=20)

## Pharmacokinetics

<a id="kisqali-metabolism"></a>

### How is Kisqali metabolized?

> “Ribociclib undergoes extensive hepatic metabolism mainly via CYP3A4 in humans. Following oral administration of a 
> single 600 mg dose of radio-labeled ribociclib to humans, the primary metabolic pathways for ribociclib involved oxidation 
> (dealkylation, C and/or N-oxygenation, oxidation (-2H)) and combinations thereof. Ribociclib was the major circulating 
> drug-derived entity in plasma (44%). The major circulating metabolites included metabolite M13 (CCI284, N-
> hydroxylation), M4 (LEQ803, N-demethylation), and M1 (secondary glucuronide), each representing an estimated 9%, 9%, 
> and 8% of total radioactivity, and 22%, 20%, and 18% of ribociclib exposure. Clinical activity of ribociclib was due 
> primarily to parent drug, with negligible contribution from circulating metabolites.”

Source: [KISQALI: Prescribing information, page 20, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=20)

<a id="kisqali-half-life"></a>

### What is the half-life of Kisqali?

> “The mean plasma effective half-life (CV%) was 32.0 hours (63%) and the mean apparent oral clearance (CL/F) was 
> 25.5 L/hr (66%) at steady-state following 600 mg dose of KISQALI in patients with advanced cancer.”

Source: [KISQALI: Prescribing information, page 20, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=20)

> “The mean apparent plasma terminal half-life of ribociclib ranged from 29.7 to 54.7 hours and mean CL/F of ribociclib 
> ranged from 39.9 to 77.5 L/hr at 600 mg across studies in healthy adults.”

Source: [KISQALI: Prescribing information, page 21, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=21)

> “Following repeated 600 mg once daily administration, steady-state was generally achieved after 8 days and ribociclib 
> accumulated with a mean accumulation ratio of 2.5 (range, 0.97 to 6.4)”

Source: [KISQALI: Prescribing information, page 20, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=20)

<a id="kisqali-excretion"></a>

### How is Kisqali eliminated from the body?

> “Following a single oral dose of radio-labeled ribociclib in healthy adults, 92% of the total administered radioactive dose was 
> recovered within 22 days; 69% in feces and 23% in urine.”

Source: [KISQALI: Prescribing information, page 21, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=21)

> “Ribociclib was extensively metabolized with unchanged drug accounting for 17% and 12% in feces and urine, respectively.”

Source: [KISQALI: Prescribing information, page 20, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=20)

## Components

<a id="kisqali-inactive-ingredients"></a>

### What are the inactive ingredients in Kisqali?

> “KISQALI film-coated tablets are supplied for oral use and contain 200 mg of ribociclib free base (equivalent to 254.40 mg 
> ribociclib succinate). The tablets also contain colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium 
> stearate and microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl 
> alcohol (partially hydrolysed), talc, titanium dioxide, and xanthan gum as inactive ingredients.”

Source: [KISQALI: Prescribing information, page 19, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=19)

## Related pages
- [Medical information: Kisqali (ribociclib): All indications](https://www.evicenter.com/medical-information/kisqali)
- [Indication](https://www.evicenter.com/medical-information/kisqali/indication)
- [Safety](https://www.evicenter.com/medical-information/kisqali/safety)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kisqali/storage-and-supply)
